natgillin/translations-raw huggingface dataset:
I tilfælde med meget alvorlige infektioner kan dosis øges til en maksimal daglig dosis på 1200 mg (400 mg tre gange dagligt).
In case of very severe infections the dose can be increased up to a maximum daily dose of 1200 mg (400 mg thrice daily).
Følgende indikationer kan overvejes til behandling med Ciprofloxacin Hikma, når oral behandling ikke er mulig eller er upålidelig: - komplicerede urinvejsinfektioner - infektioner af nedre luftveje, herunder lungebetændelse forårsaget af aerobe gram-negative bakterier.
The following indications can be considered for treatment with Ciprofloxacin Hikma when oral therapy is not possible or not reliable: - complicated urinary tract infections - infections of the lower respiratory tract including pneumonia caused by aerobic gram-negative bacteria, in case of Streptococcus pneumoniae infections ciprofloxacin is not the substance of first choice.
Der skal foretages bakteriologiske sensitivitetstest inden indledning af behandling.
Prior to initiation of therapy, bacteriological sensitivity tests should be conducted.
Hypersensitivitetsreaktioner og allergiske reaktioner forekom i nogle tilfælde efter den første administration af ciprofloxacin.
Hypersensitivity reactions and allergic reactions occurred in some cases after the first administration of ciprofloxacin.
Ciprofloxacin Hikma er et antibiotikum.
Ciprofloxacin Hikma is an antibiotic.
Bivirkningerne påvirker oftest maven og tarmene, nervesystemet og huden og bindevævet.
Most frequent side effects affect the stomach and intestine, the nervous system and the skin and connective tissue.
Ciprofloxacin hæmmer DNA-gyrase, hvilket resulterer i inhibition af DNA-syntese.
Ciprofloxacin inhibits DNA-gyrase, resulting in inhibition of DNA synthesis.
I dette tilfælde skal behandling med ciprofloxacin indstilles, og der skal gives medicinsk behandling mod shock.
In that case, the ciprofloxacin treatment must be discontinued, and medical treatment for shock should be given.
Ciprofloxacin er effektivt in vitro mod en lang række Gram-negative aerobe bakterier, inklusiv P. aeruginosa.
Ciprofloxacin is effective in vitro against a large number of Gram-negative aerobic bacteria including P. aeruginosa.
Samtidig administration af ciprofloxacin og mexiletin kan føre til forhøjede plasmakoncentrationer af mexiletin.
Simultaneous administration of ciprofloxacin and mexiletine can lead to increased plasma concentrations of mexiletine.
Østrig - Ciprofloxacin Hikma 200 mg/100 ml Infusionslösung Tyskland - Ciprofloxacin Hikma 200 mg/100 ml Lösung zur Intravenösen Anwendung Irland - Ciprofloxacin Hikma 200 mg/100 ml Solution for Infusion Italien - Ciprofloxacin Hikma 200 mg/100 ml Soluzione per Infusione Endovenosa Storbritannien - Ciprofloxacin Hikma 200 mg/100 ml Solution for Infusion Nederlandene - Ciprofloxacine Hikma 200 mg/100 ml Oplossing voor Intraveneuze Infusie
This medicinal product is authorised in the Member States of EEA under the following names: Austria - Ciprofloxacin Hikma 200mg/100ml Infusionslösung Germany - Ciprofloxacin Hikma 200mg/100ml Lösung zur Intravenösen Anwendung Ireland - Ciprofloxacin Hikma 200mg/100ml Solution for Infusion Italy - Ciprofloxacin Hikma 200mg/100ml Soluzione per Infusione Endovenosa United Kingdom - Ciprofloxacin Hikma 200mg/100ml Solution for Infusion The Netherlands - Ciprofloxacine Hikma 200mg/100ml Oplossing voor Intraveneuze Infusie
• patienter med hypersensitivitet over for ciprofloxacin, derivater af quinolincarboxylsyre eller nogle af hjælpestofferne
• patients with a hypersensitivity to ciprofloxacin, quinoline carboxylic acid derivatives or to any of the excipients
Ciprofloxacin kan forværre symptomerne på denne sygdom.
Ciprofloxacin can exacerbate the symptoms of this disease.
I tilfælde af alvorlig og vedvarende diarré under eller efter behandling med ciprofloxacin eller anden fluorquinolon skal man være opmærksom på den mulige forekomst af pseudomembranøs colitis (livstruende med risiko for dødeligt udfald).
When during or after the treatment with ciprofloxacin or another fluoroquinolone severe and persistent diarrhoea occurs, pseudomembranous colitis must be taken into account (life-threatening with possibly fatal outcome).
Saltsyre (E 507) til justering af pH Vand til injektioner
Hydrochloric acid (E 507) for pH adjustment Water for injections
• børn og unge i voksealderen bortset fra behandlingen af akutte exacerbationer af cystisk fibrose hos børn i alderen 5-17 år
• children and growing adolescents except for the treatment of acute pulmonary exacerbations of cystic fibrosis in children aged 5 to 17 years.
Ciprofloxacin Hikma påvirker i mindre eller moderat grad evnen til at føre motorkøretøj eller betjene maskiner.
Ciprofloxacin Hikma has minor or moderate influence on the ability to drive and use machines.
På grund af risikoen for arthropati og anden potentiel alvorlig toksicitet hos spædbarnet, er ciprofloxacin kontraindiceret under amning (se pkt.
Due to the risk of arthropathy and other potentially severe toxicity in the infant, ciprofloxacin is contraindicated during lactation (see section 4.3).
Derudover bør den maksimale daglige dosis af ciprofloxacin fastsættes til 400 mg tre gange dagligt.
In addition the maximum daily dose for the use of ciprofloxacin should be 400 mg three times daily.
Staphylococcus aureus (methicillin følsomme) Streptococcus spp.
Staphylococcus aureus (methicillin susceptible) Streptococcus spp.
Ikke almindelig: stigning i blodets kreatininniveauer, stigning i blodurea; unormale testresultater for leverfunktionen (øget SGOT og SGPT), bilirubinæmi og øget alkalinfosfatase.
Uncommon: increase of blood creatinine levels, increased blood urea; abnormal liver function test results (increased SGOT and SGPT), bilirubinemia and increased alkaline phosphatase.
Hos patienter med epilepsi eller andre beskadigelser af centralnervesystemet (f.eks. nedsat krampetærskel, tidligere anfald, nedsat cerebral blodgennemstrømning, forandringer i hjernestrukturen eller slagtilfælde), må ciprofloxacin kun anvendes efter nøje afvejning af fordelene i forhold til risikoen, da muligheden for bivirkninger, der stammer fra centralnervesystemet medfører øget risiko for disse patienter.
In patients with epilepsy or other lesions of the central nervous system (e.g. reduced convulsion threshold, a history of epileptic seizures, diminished cerebral blood flow, changes in brain structure or stroke), ciprofloxacin is only to be used after carefully weighing the benefits against the risk, because the possibility of central nervous side effects puts these patients at increased risk.
I lighed med andre quinoloner kan ciprofloxacin forstærke virkningen af derivater af coumarin, herunder warfarin.
Ciprofloxacin, like other quinolones, may enhance the effect of coumarin derivates including warfarin.
Opbevar hætteglasset i den ydre karton, indtil anvendelsen for at beskytte mod lys.
Keep the vial in the outer carton until time of use in order to protect from light.
Ciprofloxacin Hikma kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, Ciprofloxacin Hikma can cause side effects, although not everybody gets them.
Der er rapporter om lokalreaktioner efter intravenøs administration af ciprofloxacin.
Local reactions have been reported after intravenous administration of ciprofloxacin.
• graviditet og amning
• pregnancy and lactation
Sjælden: svedafsondring.
Rare: transpiration.
Andet:
Others:
Ciprofloxacins mutagenicitet er ikke indikeret i mutagenicitetsundersøgelser.
Mutagenicity of ciprofloxacin has not been indicated in mutagenicity studies.
Du bør tale med din læge, hvis du ammer dit barn.
You should consult your doctor if you are breast-feeding your child.
Ciprofloxacin Hikma doseringen er baseret på infektionens sværhedsgrad og type, patogenet/patogenernes følsomhed, din alder, vægt og nyrefunktion.
The Ciprofloxacin Hikma dosage is based on the severity and type of the infection, the sensitivity of the pathogen(s), your age, weight and kidney function.
De hyppigste bivirkninger involverer mave-tarmkanalen og centralnervesystemet.
Most frequent adverse effects involve the gastro-intestinal tract and the central nervous system.
• kaffein (stimulerende middel), pentoxifyllin (bruges til behandling af kredsløbslidelser i ben eller arme) and mexiletin (bruges til behandling af uregelmæssigt hjerteslag).
• caffeine (used as a stimulant), pentoxifylline (used to treat circulatory disorders in the limbs) and mexiletine (used to treat irregular heart beat).
Sygdommen påvirker lungerne, svedkirtlerne og fordøjelsessystemet og giver kroniske åndedræts- og fordøjelsesproblemer.
It affects the lungs, sweat glands and the digestive system causing chronic respiratory and digestive problems.
Hvis kreatininclearance er ≤ 30 ml/minut/1,73 m2, eller serumkreatininkoncentrationen er ≥ 175 µmol/l, er den maksimale daglige intravenøse dosis 400 mg.
If creatinine clearance is ≤ 30 ml/minute/1.73 m2 or the serum creatinine concentration is ≥ 175 µmol/l, the maximum daily intravenous dose is 400 mg.
Som ved andre gyrase-inhibitorer kan ciprofloxacin fremkalde ledskader hos unge dyr i vækstfasen.
Like with other gyrase inhibitors, ciprofloxacin may induce joint damage during the growth phase of juvenile animals.
Nedsat leverfunktion: Det er ikke nødvendigt at justere dosis i tilfælde med nedsat leverfunktion.
Impaired hepatic function: In case of impaired hepatic function it is not necessary to adjust the dosage.
Meget sjælden: tendinitis (især af achillessenen), delvise eller totale senerupturer (især af achillessenen), forværring af symptomerne på myastheni, muskelsmerter, seneskedehindebetændelse (tenosynovitis).
Very rare: tendinitis (in particular of the Achilles tendon), partial or total tendon ruptures (in particular of the Achilles tendon), worsening of the symptoms of myasthenia, muscular pains, inflammation of tendon sheaths (tenosynovitis).
Ikke almindelig: eosinophili, leukopeni.
Uncommon: eosinophilia, leukopenia.
Mælkesyre (E270), natriumchlorid, saltsyre (E507) og vand til injektion.
Lactic acid (E270), sodium chloride, hydrochloric acid (E507) and water for injection.
E. coli multi-resistent
E. coli multi-resistant Providencia spp.
Til behandling af akutte lungebetændelser forårsaget af Pseudomonas aeruginosa-bakterier hos børn og unge (5-17 år) med cystisk fibrose gives 15 mg ciprofloxacin per kg legemsvægt to gange dagligt eller 10 mg ciprofloxacin per kg legemsvægt tre gange dagligt (maksimalt 1200 mg dagligt).
For the treatment of acute pulmonary infections caused by Pseudomonas aeruginosa bacteria in children and adolescents (5-17 years) with cystic fibrosis 15 mg of ciprofloxacin per kg body weight is administered twice daily or 10 mg ciprofloxacin per kg body weight is administered three times daily (maximum 1200 mg daily).
Koagulase-negative Staphylococcus Enterococcous faecalis
Coagulase-negative Staphylococcus Enterococcous faecalis
Ciprofloxacin er et quinolon, der er effektivt in vitro mod en lang række gramnegative aerobe bakterier foruden visse grampositive organismer.
Ciprofloxacin is a quinolone effective in vitro against a large number of Gram-negative aerobic bacteria as well as against some Gram-positive organisms.
• Ciprofloxacin kan hæmme udskillelsen af methotrexat i nyren, hvilket forårsager et øget niveau af methotrexat i blodet.
• Ciprofloxacin may inhibit the excretion of methotrexate via the kidney, causing an increased methotrexate level in the blood.
Følgende er tegn på allergiske reaktioner: et skarpt fald i blodtrykket, bleghed, rastløshed, svag/hurtig puls, klam hud, svimmelhed.
Signs of these reactions are: a sharp drop in blood pressure, paleness, restlessness, weak/rapid pulse, clammy skin, dizziness.
I sådanne tilfælde skal behandling med ciprofloxacin straks indstilles, og en passende behandling påbegyndes.
In that case the ciprofloxacin therapy must immediately be discontinued and an appropriate treatment initiated.
Ciprofloxacin kan forårsage en forværring af Myastenia gravis-symptomer.
Ciprofloxacin may cause an exacerbation of Myastenia gravis symptoms.
Efter oral administration udskilles 45 % uændret i urinen og 25 % i afføringen.
After oral administration 45% is excreted unchanged in the urine and 25% is excreted in the faeces.
1 ml infusionsvæske, opløsning indeholder:
1 ml solution for infusion contains:
Ciprofloxacin-laktat, der svarer til 2 mg ciprofloxacin.
Ciprofloxacin lactate equivalent to 2 mg ciprofloxacin.
Der er set reversibel nyreskade ved akut og ekstrem overdosering.
In acute and extreme overdosage, reversible kidney damage is seen.
Hvis sådanne reaktioner opstår, skal behandling med ciproflaxacin seponeres øjeblikkeligt, og den behandlende læge skal informeres.
If such reactions occur, treatment with ciprofloxacin must be discontinued immediately and the treating physician informed.
Den af ansøgeren forelagte publicerede litteratur og resistensdata giver i det væsentlige tilfredsstillende dokumentation både for virkningen og for sikkerheden (idet der med denne dosering er større sandsynlighed for undgåelse af resistensdannelse uden stigning i bivirkningsfrekvensen) af ciprofloxacin i en dosering på 200-400 mg to gange dagligt til behandling af komplicerede urinvejsinfektioner.
The body of published literature and resistance data presented by the applicant provided adequate justification, both from an efficacy and safety (more likely to prevent bacterial resistance and no increase in adverse reactions) viewpoint, for the dosing regimen of 200-400 mg ciprofloxacin twice daily for the treatment of complicated UTI.
Nedsat nyrefunktion: Hos patienter med en kreatininclearance i området 31 - 60 ml/minut/1,73 m2 eller en serumkreatininkoncentration i området 124 - 174 µmol/l er den maksimale daglige intravenøse dosis 800 mg.
In patients with a creatinine clearance in the range 31 - 60 ml/minute/1.73 m2 or a serum creatinine concentration in the range 124 - 174 µmol/l, the maximum daily intravenous dose is 800 mg.
Børn og unge
Children and Adolescents
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER 1 ml infusionsvæske, opløsning indeholder: Ciprofloxacin laktat, der svarer til 2 mg ciprofloxacin.
STATEMENT OF ACTIVE SUBSTANCE(S) 1 ml solution for infusion contains : Ciprofloxacin lactate equivalent to 2 mg ciprofloxacin.
Al uanvendt opløsning samt hætteglasset skal bortskaffes på hensigtsmæssig vis i overensstemmelse med lokale retningslinier.
Any unused solution and the vial should be adequately disposed of in accordance with local requirements.
Disse lægemidlers niveau i blodet kan ligeledes øges.
The blood level of these medicines can be increased.
Sjælden: synkope (besvimelse), vasodilatation (varmestress).
Rare: syncope (fainting), vasodilation (heat stress).
Patienter, som får behandling med methotrexat, bør derfor overvåges nøje, når konkomitant ciprofloxacin-behandling er indiceret.
Therefore, patients receiving methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
Varigheden af behandling med Ciprofloxacin Hikma er baseret på infektionens sværhedsgrad, behandlingens virkning og den sygdomsfremkaldende følsomhed.
The duration of treatment with Ciprofloxacin Hikma is based on the severity of the infection, the effect of the treatment and the sensitivity of the pathogen(s).
Koncentrationen af ciprofloxacin i vabelvæske, lymfevæske, næsesekret, peritonealvæske, spyt og fedtvæv er ca. halvdelen af serumkoncentrationen.
The ciprofloxacin concentration in blister fluid, lymph, nasal secretion, peritoneal fluid, saliva and fatty tissue is approximately half of the serum concentration.
Du må hverken køre bil, motorcykel eller cykle eller arbejde med værktøj eller maskiner, der kræver din fulde koncentration, hvis du er svimmel.
If you suffer from dizziness, do not drive or operate machines, which require your full concentration.
Sjælden: leukopeni (granulocytopeni), anæmi, leukocytosis, ændrede protrombinværdier, trombocytopeni, trombocytæmi (thrombocytose).
Rare: leukopenia (granulocytopenia), anaemia, leukocytosis, altered prothrombin values, thrombocytopenia, thrombocytemia (thrombocytosis).
Symptomer på overdosis kan inkludere svimmelhed, tremor, hovedpine, træthed, krampeanfald, hallucinationer, konfusion, maveonde, anomalier i lever og nyre, krystalluri, hæmaturi.
Symptoms of overdose may include dizziness, tremor, headaches, tiredness, seizures, hallucinations, confusion, gastrointestinal upset, liver and kidney abnormalities, crystalluria, haematuria.
Ciprofloxacin Hikma kan også administreres ved behandling af akutte infektioner i de nedre luftveje forårsaget af Pseudomonas aeruginosa hos børn mellem 5-17 år med cystisk fibrose.
Ciprofloxacin Hikma may also be administered in the treatment of acute lower respiratory tract infections caused by Pseudomonas aeruginosa in children aged 5-17 years with cystic fibrosis.
Probenecid hæmmer nyreudskillelsen af ciprofloxacin, hvilket resulterer i en stigning af plasmakoncentrationen af ciprofloxacin.
Probenecid inhibits the renal excretion of ciprofloxacin resulting in an increase in the plasma concentration of ciprofloxacin.
Ciprofloxacin hæmmer dette enzym.
Ciprofloxacin inhibits this enzyme.
Renal tubulær transport af methotrexat kan hæmmes af konkomitant administration af ciprofloxacin og potentielt føre til forhøjede plasmaniveauer af methotrexat.
Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin potentially leading to increased plasma levels of methotrexate.
Du må ikke tage Ciprofloxacin Hikma under graviditet.
You must not be given Ciprofloxacin Hikma during pregnancy.
Aktivt stof: ciprofloxacin-laktat.
The active substance is ciprofloxacin lactate.
Ciprofloxacin Hikma bruges til behandling af alvorlige og/eller livstruende infektioner forårsaget af ciprofloxacin-følsomme mikroorganismer.
Ciprofloxacin Hikma is used for the treatment of severe and/or life-threatening infections caused by ciprofloxacin-sensitive microorganisms.
Som ved andre lægemidler i denne gruppe er det rapporteret, at ciprofloxacin forårsager ledsygdomme i de vægtbærende led hos ikke-udvoksede dyr.
As for other medicinal products in this group, ciprofloxacin has been reported to cause joint disorders in weight-bearing joints of immature animals.
Denne medicin kan give disse bivirkninger, især hvis du er ældre eller tager medicin af den såkaldte sterioide-gruppe, f.eks. hydrocortison.Hvis du får disse symptomer, skal du straks tale med din læge og hvile det pågældende ben.
This medicine may cause these side effects, particularly if you are older or take a medicine of the socalled steroid group, such as hydrocortisone.
INDHOLDSMÆNGDE ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER Præsentation af 200 mg/100 ml: 100 ml
EXPIRY DATE EXP {MM/YYY} BATCH NUMBER Batch nr. {xxxxxx} CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT Presentation of 200 mg/100 ml: 100 ml OTHER
• Præmedicinering (bruges, før der gives narkosemiddel): det anbefales, at præmedicinering med opiater, (f.eks. papaveretum) eller præmedicinering med opiater sammen med anticholiner præmedicinering (f.eks. atropin eller hyoscin) ikke bruges samtidigt med ciprofloxacin, da serumniveauet af ciprofloxacin reduceres.
• Pre-medicants (used before anaesthesia induction): it is recommended that opiate pre-medicants, (e.g. papaveretum) or opiate pre-medicants used with anticholinergic pre-medicants, (e.g. atropine or hyoscine) are not used concomitantly with ciprofloxacin, as the serum levels of ciprofloxacin are reduced.
4.4 med hensyn til sikkerheden og brugen af ciprofloxacin til børn
With regard to the safety and use of ciprofloxacin in children, see also section 4.4
søvnforstyrrelse (søvnløshed), rastløshed (agitation), forvirring - kvalme, diarré - udslæt
difficulty in sleeping (insomnia), restlessness (agitation), confusion - nausea, diarrhoea - rash
Staphylococcus epidermidis Staphylococcus haemolyticus Gram-negative aerober
Staphylococcus haemolyticus Gram-negative aerobes
Break points ikke relateret til arter er ≤ 0,5 µg/ml for følsomme og > 1 µg/ml for resistente organismer.
Non-species related breakpoints are ≤ 0,5 µg/ml for susceptible, and > 1 µg/ml for resistant organisms.
BEGRUNDELSE FOR ÆNDRINGEN AF PRODUKTRESUMÉ, ETIKETTERING OG INDLÆGSSEDDEL
GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET
Ciprofloxacin Hikma indeholder 15,4 mmol (354 mg) natrium pr. 100 ml infusionsvæske, opløsning.
Ciprofloxacin Hikma contains 15.4 mmol (354 mg) sodium per 100 ml of solution for infusion.
• hvis du ammer
• If you are breast-feeding.
Centralnervesystem:
Central nervous system:
Opiatpræmedikation (f.eks. papaveretum) eller opiatpræmedikation, der bruges med antikolinerg præmedikation (f.eks. atropin eller hyoscin), bør ikke anvendes sammen med ciprofloxacin, da serumniveauerne af ciprofloxacin reduceres.
It is recommended that opiate premedicants, (e.g. papaveretum) or opiate premedicants used with anticholinergic premedicants, (e.g. atropine or hyoscine) are not used concomitantly with ciprofloxacin, as the serum levels of ciprofloxacin are reduced.
• Mycobacerium tuberculosis-test. Du bedes underrette din læge, når du behandles med Ciprofloxacin Hikma, da resultatet af denne test kan være falsk.
Please inform your doctor when under treatment with Ciprofloxacin Hikma as the result of this test may be false.
Den fortyndede opløsning bør inspiceres visuelt for partikler og misfarvning inden indgivelse.
The diluted solution should be inspected visually for particulate matter and discoloration prior to administration.
Behandlingen skal indstilles, når fotosensitivitet forekommer.
When photosensibility occurs the treatment must be discontinued.
Du bør tale med din læge, hvis du selv eller nogen i din familie har denne sygdom.
If you or someone in your family suffers from this disease, you should consult your doctor.
• Opbevares i den originale yderpakning indtil brug for at beskytte mod lys.
• Keep the vial in the outer carton until time of use in order to protect from light.
Øvrige indholdsstoffer: mælkesyre (E270), natriumchlorid, saltsyre (E507) til justering af pH-værdi og vand til injektioner.
The other ingredients are lactic acid (E270), sodium chloride, hydrochloric acid (E507) for pH adjustment and water for injections.
Den sædvanlige dosis til voksne er 200-400 mg ciprofloxacin to gange dagligt.
The usual dose in adults is 200-400 mg of ciprofloxacin twice daily.
Dosering til voksne er 200 - 400 mg ciprofloxacin to gange dagligt.
The adult dosage is 200 - 400 mg ciprofloxacin twice daily.
Ciprofloxacin Hikma er kontraindiceret til:
Ciprofloxacin Hikma is contraindicated in:
Meget sjælden: parosmi (nedsat lugtesans), anosmi (forsvinder normalt efter afbrydelse), grand malanfald, unormal (ustabil) gang, intrakraniel hypertension, ataksi, hyperæstesi, hypertoni.
Very rare: parosmia (impaired smell), anosmia (usually reversible after interruption), grand mal convulsion, abnormal (unstable) gait, intracranial hypertension, ataxia, hyperesthesia, hypertonia.
Sjælden: icterus, cholestatisk icterus, levercelle nekrose.
Rare: icterus, cholestatic icterus, liver cell necrosis.
Øjne: Sjælden: synsforstyrrelser, diplopi, chromatopsi.
Eye disorders: Rare: disturbed vision, diplopia, chromatopsia.
Meget sjælden: vasculitis (petechiae, hæmorragiske bullae, papula, skorpedannelse).
Very rare: vasculitis (petechiae, hemorrhagic bullae, papules, crust formation).
Der skal udvises særlig forsigtighed, hvis Ciprofloxacin Hikma gives samtidig med noget af følgende medicin:
Using other medicines If Ciprofloxacin Hikma and one of the following medicines are given at the same time, special care should be taken:
Luftveje, thorax og mediastinum: Sjælden: dyspnø, laryngealt ødem.
Respiratory, thoracic and mediastinal disorders: Rare: dyspnoea, laryngeal oedema.